Abstract
AbstractBackground:CYP1A2 and CYP2A6 are polymorphic drug-metabolising enzymes that are also implicated in the activation of procarcinogens in humans. Some of their alleles and haplotypes, often varied in prevalence across populations, are thought to influence activity despite the known contribution of environmental factors. This study assessed the potential influence of some genetic variants ofMethods:Genomic DNA was extracted from blood samples of 100 healthy, unrelated subjects for whom CYP1A2 and CYP2A6 phenotypes had previously been determined, alongside an additional 80 other individuals for whom phenotype data were unavailable. The samples were screened forResults:All fiveConclusions:Our findings suggest that
Subject
Pharmacology (medical),General Pharmacology, Toxicology and Pharmaceutics
Reference96 articles.
1. Frequencies of four genetic polymorphisms in the CYP1A2 gene in Turkish population;Genetika,2008
2. Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the genotype-phenotype relationship in Swedes and Koreans;Eur J Clin Pharmacol,2007
3. To genotype or phenotype for personalized medicine? CYP450 drug metabolizing enzyme genotype-phenotype concordance and discordance in the Ecuadorian population;OMICS,2016
4. Rapid genotyping for relevant CYP1A2 alleles by pyrosequencing;Eur J Clin Pharmacol,2005
5. Cytochrome P450 polymorphism – molecular, metabolic, and pharmacogenetic aspects. II. Participation of CYP isoenzymes in the metabolism of endogenous substances and drugs;Acta Pol Pharm,2008
Cited by
8 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献